BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON: Form 990, tax year 2017
View the entire original 990 at ProPublica ↗
- Organization
- BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (EIN 91-0653422)
- Tax period
- 2017-01-01 to 2017-12-31
- Filed
- 2018-11-12
- IRS object ID
- 201843169349305324
- Schema version
- 2017v2.3
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule K
- Schedule O
- Schedule R
- Affiliated Group Schedule
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2018-11-12T05:37:06-00:00 | ReturnTs |
| Tax Period End | 2017-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1918 8th Avenue Suite 2900 | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98101 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2017-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 910653422 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Benaroya Research Institute at Virginia Mason | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | BENA | BusinessNameControlTxt |
| Phone | 2063426500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1201 Ninth Avenue | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 981012795 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | Homer W Lane Jr | PersonNm |
| Person Title | Executive DirectorCFO | PersonTitleTxt |
| Signature | 2018-11-12 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | Sue Robison | PreparerPersonNm |
| Phone | 2069134000 | PhoneNum |
| Preparation | 2018-11-12 | PreparationDt |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 204.147.223.1 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IP | 2018-11-13 | IPDt |
| IP Tm | 01:33:39 | IPTm |
| IP Timezone | PS | IPTimezoneCd |
| Filing License Type | P | FilingLicenseTypeCd |
| At Submission Creation Device Id | 3BF9F3C1D5421FE41D537B7E0F61F32192DE8497 | AtSubmissionCreationDeviceId |
| At Submission Filing Device Id | 3BF9F3C1D5421FE41D537B7E0F61F32192DE8497 | AtSubmissionFilingDeviceId |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2017 | TaxYr |
| Build TS | 2019-02-21 02:37:17Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | Jane Buckner MD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1201 Ninth Avenue | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98101 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $68,019,757 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | http://www.benaroyaresearch.org | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1956 | FormationYr |
| Legal Domicile State | WA | LegalDomicileStateCd |
| Activity Or Mission | To conduct and encourage high quality medical, surgical, and scientific research and research training in disease and problems of medical importance. | ActivityOrMissionDesc |
| Voting Members Governing Body | 20 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 15 | VotingMembersIndependentCnt |
| Total Employee | 332 | TotalEmployeeCnt |
| Total Volunteers | 4 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $71,346,495 | PYContributionsGrantsAmt |
| CY Contributions Grants | $60,243,416 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $8,553,010 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $6,781,431 | CYProgramServiceRevenueAmt |
| PY Investment Income | $394,767 | PYInvestmentIncomeAmt |
| CY Investment Income | $456,650 | CYInvestmentIncomeAmt |
| PY Other Revenue | $347,680 | PYOtherRevenueAmt |
| CY Other Revenue | $347,680 | CYOtherRevenueAmt |
| PY Total Revenue | $80,641,952 | PYTotalRevenueAmt |
| CY Total Revenue | $67,829,177 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $29,786,250 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $27,587,861 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $25,664,449 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $25,600,727 | CYSalariesCompEmpBnftPaidAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $19,506,635 | PYOtherExpensesAmt |
| CY Other Expenses | $18,423,765 | CYOtherExpensesAmt |
| PY Total Expenses | $74,957,334 | PYTotalExpensesAmt |
| CY Total Expenses | $71,612,353 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $5,684,618 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$3,783,176 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $91,306,270 | TotalAssetsBOYAmt |
| Total Assets EOY | $90,102,675 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $44,301,004 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $44,389,195 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $47,005,266 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $45,713,480 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | Advancing the science that will predict, prevent, reverse and cure diseases of the immune system, such as autoimmune disease, allergy and asthma. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $32,265,013 | ExpenseAmt |
| Grant | $23,471,602 | GrantAmt |
| Desc | Immune Tolerance Network Program. See Schedule O. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $8,738,789 | ExpenseAmt |
| Grant | $1,714,167 | GrantAmt |
| Desc | Translational Program. See Schedule O. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $6,862,100 | ExpenseAmt |
| Grant | $1,293,149 | GrantAmt |
| Desc | Diabetes Progra. See Schedule O. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $12,940,377 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $1,108,943 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $6,781,431 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $60,806,279 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (true) | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | false | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Temp Or Permanent Endowments | Yes (true) | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | Yes (true) | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | false | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (true) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | false | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | false | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | false | ProfessionalFundraisingInd |
| Fundraising Activities | false | FundraisingActivitiesInd |
| Gaming Activities | false | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | false | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | Yes (true) | TaxExemptBondsInd |
| Invest Tax Exempt Bonds | false | InvestTaxExemptBondsInd |
| Escrow Account | false | EscrowAccountInd |
| On Behalf Of Issuer | Yes (true) | OnBehalfOfIssuerInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | false | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | false | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | false | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | false | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| IRP Document | 104 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 332 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | false | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | false | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 20 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 15 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (true) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (true) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | Yes (true) | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | false | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (true) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | Homer W Lane Jr Executive DirectorC | PersonNm |
| Phone | 2063426508 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1201 Ninth Avenue | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 981012795 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (27 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| Jane Buckner MD | |||||||||
| Ex Officio, President | 040.00 | Yes (X) | Yes (X) | $314,832 | $0 | $24,936 | |||
| Carla Greenbaum MD | |||||||||
| Director | 040.00 | Yes (X) | $224,224 | $0 | $30,384 | ||||
| Joyce Lammert MD PhD | |||||||||
| Director | 001.00 | Yes (X) | $0 | $486,335 | $26,476 | 050.00 | |||
| John Corman MD | |||||||||
| Director | 001.00 | Yes (X) | $0 | $597,283 | $72,982 | 050.00 | |||
| Gary Kaplan MD | |||||||||
| Director | 001.00 | Yes (X) | $0 | $1,127,597 | $68,995 | 054.00 | |||
| Tom Cohen | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Rebecca Campbell | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Margaret Morrow | |||||||||
| Director, Secretary | 001.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| Frank Dvorak PhD | |||||||||
| Director, Vice Chair | 001.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| Patricia Markey | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| David Williams | |||||||||
| Director, Treasurer | 001.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | 004.00 | ||
| W Michael Gallatin PhD | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Jessica Muffett | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Carla DewBerry | |||||||||
| Director, Chair | 001.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| Christopher Wilson MD | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Nabil Istafanous | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Ben Rieber | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Jeffrey Wortley | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Catherine Zimmerman | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Diane St John MBA | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Homer Lane Jr | |||||||||
| Executive Director, CFO | 040.00 | Yes (X) | $262,308 | $0 | $33,306 | ||||
| Gerald Nepom MD PhD | |||||||||
| Program Director, ITN | 024.00 | $149,222 | $0 | $27,192 | Yes (X) | ||||
| Willliam Kwok PhD | |||||||||
| Research Member | 040.00 | $229,415 | $0 | $27,336 | Yes (X) | ||||
| Steven Ziegler PhD | |||||||||
| Director of Academic Affairs | 040.00 | $220,724 | $0 | $21,612 | Yes (X) | ||||
| James Lord MD | |||||||||
| Research Member | 040.00 | $199,380 | $0 | $22,110 | Yes (X) | ||||
| Lynn Rose PhD | |||||||||
| Director Scientific Administration | 040.00 | $186,196 | $0 | $24,930 | Yes (X) | ||||
| Philip Bernstein | |||||||||
| Research Member | 040.00 | $176,076 | $0 | $24,744 | Yes (X) | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $1,962,377 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $2,211,215 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $405,003 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 51 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | false | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (3 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| Finley & Cook PLLC | |||||
| 601 North Broadway | Shawnee | OK | 74801 | Consulting | $153,505 |
| KPMG LLP | |||||
| 1918 Eight Ave Suite 2900 | Seattle | WA | 98101 | Auditing Consulting | $119,227 |
| Riverbend Design Group LLC | |||||
| 414 Stewart St siote 215 | Seattle | WA | 98101 | Consulting | $101,100 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 3 | CntrctRcvdGreaterThan100KCnt |
| Related Organizations | $1,750,000 | RelatedOrganizationsAmt |
| Government Grants | $51,827,654 | GovernmentGrantsAmt |
| All Other Contributions | $6,665,762 | AllOtherContributionsAmt |
| Total Contributions | $60,243,416 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| Commercial Studies | 621500 | $3,568,126 | $3,568,126 |
| Collaborative Research Core Services | 621500 | $3,213,305 | $3,213,305 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $6,781,431 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $456,650 | TotalRevenueColumnAmt |
| Exclusion | $456,650 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $538,260 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $190,580 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $347,680 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $347,680 | TotalRevenueColumnAmt |
| Exclusion | $347,680 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $67,829,177 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $6,781,431 | RelatedOrExemptFuncIncomeAmt |
| Exclusion | $804,330 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $26,209,077 | TotalAmt |
| Program Services | $26,209,077 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,378,784 | TotalAmt |
| Program Services | $1,378,784 | ProgramServicesAmt |
Benefits To Members BenefitsToMembersGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $959,603 | TotalAmt |
| Program Services | $574,149 | ProgramServicesAmt |
| Management And General | $385,454 | ManagementAndGeneralAmt |
Comp Disqual Persons CompDisqualPersonsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $19,546,742 | TotalAmt |
| Program Services | $14,426,390 | ProgramServicesAmt |
| Management And General | $5,120,352 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,578,890 | TotalAmt |
| Program Services | $1,131,956 | ProgramServicesAmt |
| Management And General | $446,934 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,095,924 | TotalAmt |
| Program Services | $1,502,634 | ProgramServicesAmt |
| Management And General | $593,290 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,419,568 | TotalAmt |
| Program Services | $1,017,732 | ProgramServicesAmt |
| Management And General | $401,836 | ManagementAndGeneralAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $96,312 | TotalAmt |
| Management And General | $96,312 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $96,027 | TotalAmt |
| Management And General | $96,027 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fees For Services Prof Fundraising | FeesForServicesProfFundraising |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,436,749 | TotalAmt |
| Program Services | $1,704,004 | ProgramServicesAmt |
| Management And General | $732,745 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $54,855 | TotalAmt |
| Management And General | $54,855 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $110,613 | TotalAmt |
| Program Services | $20,251 | ProgramServicesAmt |
| Management And General | $90,362 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,676,142 | TotalAmt |
| Program Services | $747,050 | ProgramServicesAmt |
| Management And General | $929,092 | ManagementAndGeneralAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,787,256 | TotalAmt |
| Program Services | $2,441,621 | ProgramServicesAmt |
| Management And General | $345,635 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $335,384 | TotalAmt |
| Program Services | $274,853 | ProgramServicesAmt |
| Management And General | $60,531 | ManagementAndGeneralAmt |
Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $133,449 | TotalAmt |
| Program Services | $104,615 | ProgramServicesAmt |
| Management And General | $28,834 | ManagementAndGeneralAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $629,819 | TotalAmt |
| Program Services | $547,943 | ProgramServicesAmt |
| Management And General | $81,876 | ManagementAndGeneralAmt |
Payments To Affiliates PaymentsToAffiliatesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,696,872 | TotalAmt |
| Program Services | $2,890,809 | ProgramServicesAmt |
| Management And General | $806,063 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $41,004 | TotalAmt |
| Management And General | $41,004 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| Supplies | $3,927,286 | $3,827,326 | $99,960 |
| Other Purchased Services | $332,777 | $185,691 | $147,086 |
| Patient Costs | $1,099,995 | $1,099,995 | |
| Research Partipants Fees | $436,391 | $436,219 | $172 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $532,834 | TotalAmt |
| Program Services | $285,180 | ProgramServicesAmt |
| Management And General | $247,654 | ManagementAndGeneralAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $71,612,353 | TotalAmt |
| Program Services | $60,806,279 | ProgramServicesAmt |
| Management And General | $10,806,074 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,525,094 | BOYAmt |
| EOY | $6,125,815 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,288,001 | BOYAmt |
| EOY | $363,312 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,690,871 | BOYAmt |
| EOY | $13,584,865 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,620,548 | BOYAmt |
| EOY | $1,647,502 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $349,640 | BOYAmt |
| EOY | $400,177 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $72,695,299 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $45,459,789 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $29,599,133 | BOYAmt |
| EOY | $27,235,510 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,312,100 | BOYAmt |
| EOY | $12,181,585 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $28,068,298 | BOYAmt |
| EOY | $27,320,900 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $852,585 | BOYAmt |
| EOY | $1,243,009 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $91,306,270 | BOYAmt |
| EOY | $90,102,675 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,436,607 | BOYAmt |
| EOY | $11,146,141 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,142,907 | BOYAmt |
| EOY | $6,511,564 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $27,721,490 | BOYAmt |
| EOY | $26,731,490 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $44,301,004 | BOYAmt |
| EOY | $44,389,195 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $20,816,818 | BOYAmt |
| EOY | $18,078,247 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,225,413 | BOYAmt |
| EOY | $13,575,861 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,963,035 | BOYAmt |
| EOY | $14,059,372 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $47,005,266 | BOYAmt |
| EOY | $45,713,480 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $91,306,270 | BOYAmt |
| EOY | $90,102,675 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$3,783,176 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $2,491,390 | NetUnrlzdGainsLossesInvstAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (true) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (true) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Medical Research Organization | Yes (X) | MedicalResearchOrganizationInd |
Hospital Name And Address HospitalNameAndAddressGrp
Supported Organization Name SupportedOrganizationName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Virginia Mason Medical Center | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $44,973,133 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $54,174,085 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $59,709,893 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $71,346,495 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $60,243,416 | CurrentTaxYearAmt |
| Total | $290,447,022 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $44,973,133 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $54,174,085 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $59,709,893 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $71,346,495 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $60,243,416 | CurrentTaxYearAmt |
| Total | $290,447,022 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $27,492,877 | SubstantialContributorsTotAmt |
| Public Support Total170 | $262,954,145 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $642,011 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $707,157 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $430,555 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $933,027 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $994,910 | CurrentTaxYearAmt |
| Total | $3,707,660 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $6,122,655 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $6,639,555 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $7,021,290 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $8,553,010 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $6,781,431 | CurrentTaxYearAmt |
| Total | $35,117,941 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $329,272,623 | TotalSupportAmt |
| Public Support CY170 | 0.79860 | PublicSupportCY170Pct |
| Public Support PY170 | 0.79920 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
| Public Support CY509 | 0.00000 | PublicSupportCY509Pct |
| Investment Income CY | 0.00000 | InvestmentIncomeCYPct |
| Facts And Circumstances Test | Part II Section B Line 10 2017 Other Income of 6,781,431 is comprised of 3,568,126 of Clinical Research Program revenue, 2,855,288 of Collaborative Research Agreement projects, 318,733 of External Core Income, and 39,284 of miscellaneous income. | FactsAndCircumstancesTestTxt |
Schedule B IRS990ScheduleB
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Belongs Afflt Grp | Yes (X) | OrganizationBelongsAffltGrpInd |
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Affiliated Group Total | $175,480 | AffiliatedGroupTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Affiliated Group Total | $108,767 | AffiliatedGroupTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Affiliated Group Total | $284,247 | AffiliatedGroupTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $71,612,353 | FilingOrganizationsTotalAmt |
| Affiliated Group Total | $1,586,599,944 | AffiliatedGroupTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $71,612,353 | FilingOrganizationsTotalAmt |
| Affiliated Group Total | $1,586,884,191 | AffiliatedGroupTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
| Affiliated Group Total | $1,000,000 | AffiliatedGroupTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
| Affiliated Group Total | $250,000 | AffiliatedGroupTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $138,835 | CurrentYearMinus3Amt |
| Current Year Minus2 | $154,766 | CurrentYearMinus2Amt |
| Current Year Minus1 | $275,782 | CurrentYearMinus1Amt |
| Current Year | $284,247 | CurrentYearAmt |
| Total | $853,630 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $119,335 | CurrentYearMinus3Amt |
| Current Year Minus2 | $108,173 | CurrentYearMinus2Amt |
| Current Year Minus1 | $163,134 | CurrentYearMinus1Amt |
| Current Year | $175,480 | CurrentYearAmt |
| Total | $566,122 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | false | VolunteersInd |
| Paid Staff Or Management | false | PaidStaffOrManagementInd |
| Media Advertisements | false | MediaAdvertisementsInd |
| Mailings Members | false | MailingsMembersInd |
| Publications Or Broadcast | false | PublicationsOrBroadcastInd |
| Grants Other Organizations | false | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | false | DirectContactLegislatorsInd |
| Rallies Demonstrations | false | RalliesDemonstrationsInd |
| Other Activities | false | OtherActivitiesInd |
| Not Described Section501c3 | false | NotDescribedSection501c3Ind |
| Form4720 Filed4912 Tax | false | Form4720Filed4912TaxInd |
Supplemental Information Detail SupplementalInformationDetail (5 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| II-A A | Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. |
| II-A A continued | Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0 |
| II-A A continued | Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures, 0 Excess Lobbying Expenditures. |
| II-A A continued | Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing member. Grassroots Lobbying Expenditures 133,386 Direct Lobbying Expenditures 48,767. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2017. |
| II-A A continued | Yakima Valley Memorial Hospital Association, EIN 91-0567263, 2811 Tieton Drive, Yakima, WA 98902. Non-electing member. 42,094 Grassroots Lobbying Expenditures 60,000 Direct Lobbying Expenditures. Excess Lobbying Expenditures 0. |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Incl Escrow Custodial Acct Liab | false | InclEscrowCustodialAcctLiabInd |
| Endowments Held Unrelated Org | false | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | Yes (true) | EndowmentsHeldRelatedOrgInd |
| Related Org List Sch R | Yes (true) | RelatedOrgListSchRInd |
Land LandGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $756,906 | OtherCostOrOtherBasisAmt |
| Book Value | $756,906 | BookValueAmt |
Buildings BuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $49,523,385 | OtherCostOrOtherBasisAmt |
| Depreciation | $26,816,398 | DepreciationAmt |
| Book Value | $22,706,987 | BookValueAmt |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $196,862 | OtherCostOrOtherBasisAmt |
| Depreciation | $196,862 | DepreciationAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $21,956,200 | OtherCostOrOtherBasisAmt |
| Depreciation | $18,446,529 | DepreciationAmt |
| Book Value | $3,509,671 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $261,946 | OtherCostOrOtherBasisAmt |
| Book Value | $261,946 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $27,235,510 | TotalBookValueLandBuildingsAmt |
Other Securities OtherSecuritiesGrp (3 entries)
| DescDesc | Book ValueBookValueAmt |
|---|---|
| Financial derivatives and other financial products | |
| Closely-held equity interests | |
| Interest in Net Assets of Virginia Mason Health System | $27,320,900 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Securities | $27,320,900 | TotalBookValueSecuritiesAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | Federal income taxes | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Rev Etc Audited Fincl Stmt | $70,320,567 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $2,491,390 | NetUnrealizedGainsInvstAmt |
| Revenue Not Reported | $2,491,390 | RevenueNotReportedAmt |
| Revenue Subtotal | $67,829,177 | RevenueSubtotalAmt |
| Total Revenue Per Form990 | $67,829,177 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $71,612,353 | TotExpnsEtcAuditedFinclStmtAmt |
| Expenses Subtotal | $71,612,353 | ExpensesSubtotalAmt |
| Total Expenses Per Form990 | $71,612,353 | TotalExpensesPerForm990Amt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)
| RegionRegionTxt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|
| Europe Including Iceland and Greenland | Conferences | Medical Research | $26,129 |
| South America | Conferences | Medical Research | $3,269 |
| Middle East and North Africa | Conferences | Medical Research | $2,225 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Spent | $31,623 | SubtotalSpentAmt |
| Total Spent | $31,623 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (11 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| Europe Including Iceland and Greenland | Medical Research | $499,590 | Wire Transfer |
| Europe Including Iceland and Greenland | Medical Research | $181,386 | Wire Transfer |
| Europe Including Iceland and Greenland | Medical Research | $79,284 | Wire Transfer |
| Europe Including Iceland and Greenland | Medical Research | $49,145 | Wire Transfer |
| Europe Including Iceland and Greenland | Medical Research | $41,251 | Wire Transfer |
| North America | Medical Research | $13,630 | Wire Transfer |
| North America | Medical Research | $6,650 | Wire Transfer |
| North America | Medical Research | $6,127 | Wire Transfer |
| East Asia and the Pacific | Medical Research | $367,258 | Wire Transfer |
| East Asia and the Pacific | Medical Research | $89,180 | Wire Transfer |
| East Asia and the Pacific | Medical Research | $45,283 | Wire Transfer |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 11 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | false | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | false | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | false | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Part I Line 2 | Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. |
| Part I Line 3f | The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. |
| Part II Line 1 | The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (64 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| Ann&Robert H Lurie Children's Hospital of Chicago | |||||||
| 225 East Chicago Ave No 205 | Chicago | IL | 606112991 | 362170833 | 501c3 | $19,249 | Medical Research |
| Arkansas Children's Hospital Research Institute | |||||||
| One Childrens Way Financial Service | Little Rock | AR | 722023591 | 710694931 | 501c3 | $105,254 | Medical Research |
| Asthma Inc | |||||||
| 9725 3rd Ave NE Suite 500 | Seattle | WA | 98115 | 237219813 | 501c3 | $150,235 | Medical Research |
| Baylor Research Institute | |||||||
| 3301 Live Oak Suite 501 | Dallas | TX | 75204 | 751921898 | 501c3 | $20,414 | Medical Research |
| Brigham And Women's Hospital | |||||||
| Bank of America NA POBox 3887 | Boston | MA | 022413887 | 042312909 | 501c3 | $250,516 | Medical Research |
| Children's Hosp of Philadelphia | |||||||
| PO Box 8550 Lockbox 1457 | Philadelphia | PA | 191781457 | 231352166 | 501c3 | $51,375 | Medical Research |
| Children's Mercy Hospital | |||||||
| 2401 Gillham Road | Kansas City | MO | 64101 | 440605373 | 501c3 | $53,258 | Medical Research |
| City Of Hope | |||||||
| Attn Monrovla 2562 1500 East Duarte | Duarte | CA | 91010 | 953435919 | 501c3 | $505,000 | Medical Research |
| Columbia University Trustees of | |||||||
| PO Box 29789 General Post Office | New York | NY | 100879789 | 135598093 | 501c3 | $127,854 | Medical Research |
| Dana-Farber Cancer Institute Inc | |||||||
| 450 Brookline Ave 431C | Boston | MA | 02215 | 042263040 | 501c3 | $286,815 | Medical Research |
| Denver Nephrologists PC | |||||||
| 130 Rampart Way Suite 300B | Denver | CO | 80230 | 840591433 | $47,686 | Medical Research | |
| Dermatology Research Assoc Inc | |||||||
| 8930 S Sepulveda Blvd Ste 114 | Los Angeles | CA | 90045 | 273947370 | $26,878 | Medical Research | |
| Duke University | |||||||
| PO Box 602651 Accounts Receivable L | Charlotte | NC | 282602651 | 560532129 | 501c3 | $1,195,537 | Medical Research |
| Emory University | |||||||
| 1599 Clifton Road NE 4th floor | Atlanta | GA | 30322 | 580566256 | 501c3 | $312,990 | Medical Research |
| Feinstein Institute for Medical Research | |||||||
| 350 Community Drive | Manhasset | NY | 11030 | 112673595 | 501c3 | $54,994 | Medical Research |
| Fred Hutchinson Cancer Research Center | |||||||
| 1100 Fairview Ave N J6-330 PO Box 1 | Seattle | WA | 981091024 | 237156071 | 501c3 | $222,261 | Medical Research |
| Hospital for Special Surgery | |||||||
| 535 East 70th Street | New York | NY | 10021 | 131624135 | 501c3 | $22,260 | Medical Research |
| Icahn School of Medicine at Mount Sinai | |||||||
| One Gustave L Levy Place Box 3500 O | New York | NY | 100296574 | 136171197 | 501c3 | $273,257 | Medical Research |
| Indiana University | |||||||
| 400 E 7th St Poplars Room 501 | Bloomington | IN | 47405 | 356001673 | 501c3 | $101,322 | Medical Research |
| JDRF | |||||||
| 26 Broadway 14th Floor | New York | NY | 10004 | 231907729 | 501c3 | $19,208 | Medical Research |
| Johns Hopkins University | |||||||
| Central Lockbox c/o B of A 12529 Co | Chicago | IL | 60693 | 520595110 | 501c3 | $1,001,174 | Medical Research |
| Jonathan Corren MD Inc | |||||||
| 10780 Santa Monica Blvd 280 Allergy | Los Angeles | CA | 90025 | 462346264 | $299,704 | Medical Research | |
| Joslin Diabetes Center | |||||||
| One Joslin Place | Boston | MA | 022155306 | 042203836 | 501c3 | $99,147 | Medical Research |
| La Jolla Institute for Allergy & Immunology | |||||||
| 9420 Athena Circle | La Jolla | CA | 92037 | 330328688 | 501c3 | $135,000 | Medical Research |
| Massachusetts General Hospital | |||||||
| 55 Fruit Street Research Management | Boston | MA | 02114 | 042697983 | 501c3 | $5,643,320 | Medical Research |
| Medical University of South Carolina | |||||||
| 19 Hagood Avenue Ste 604 MSC 808 | Charleston | SC | 29425 | 576000722 | South Carolina | $123,045 | Medical Research |
| National Jewish Health | |||||||
| 1400 Jackson Street M213 | Denver | CO | 80206 | 742044647 | 501c3 | $77,378 | Medical Research |
| New York University-School of Medicine | |||||||
| PO Box 415026 Bank of America | Boston | MA | 022415026 | 135562308 | 501c3 | $75,897 | Medical Research |
| Northwestern University | |||||||
| 633 Clark Room G547 ATTN ASRSP | Evanston | IL | 60208 | 362167817 | 501c3 | $422,083 | Medical Research |
| Ohio State University | |||||||
| Office of Sponsored Programs 1960 K | Columbus | OH | 43210 | 316025986 | 501c3 | $35,561 | Medical Research |
| Oklahoma Medical Research Foundation | |||||||
| 825 NE 13th Street | Okahoma City | OK | 73104 | 730580274 | 501c3 | $129,123 | Medical Research |
| Polyclinic | |||||||
| Madison Center 904 7th Ave 6th Floo | Seattle | WA | 98104 | 910369070 | $43,061 | Medical Research | |
| Rockefeller University | |||||||
| 1230 York Ave Financial Post Award | New York | NY | 100656307 | 131624158 | 501c3 | $83,601 | Medical Research |
| Rogosin Institute Inc The | |||||||
| 505 East 70th Street 2nd Floor | New York | NY | 100214872 | 133184198 | 501c3 | $19,853 | Medical Research |
| Rutgers the State University of New Jersey | |||||||
| Office of Research and Sponsored Pr | New Brunswick | NJ | 089018559 | 226001086 | 501c3 | $504,757 | Medical Research |
| Sanford Research | |||||||
| 2301 E 60th St N Attn Clinical Rese | Sioux Falls | SD | 57104 | 460450378 | 501c3 | $75,875 | Medical Research |
| Seattle Childrens Hospital | |||||||
| PO Box 24728 | Seattle | WA | 981240728 | 910564748 | 501c3 | $678,860 | Medical Research |
| St Jude Children's Research Hospital Inc | |||||||
| PO Box 1000 Dept 949 | Memphis | TN | 381480949 | 620646012 | 501c3 | $194,776 | Medical Research |
| Stanford University | |||||||
| PO Box 44253 | San Francisco | CA | 941444253 | 941156365 | 501c3 | $784,166 | Medical Research |
| State University of Iowa | |||||||
| 118 S Clinton St - SCST Attn Grant | Iowa city | IA | 52242 | 426004813 | Iowa | $36,975 | Medical Research |
| Tulane University | |||||||
| 1430 Tulane Ave Dermatology 8036 At | New Orleans | LA | 70112 | 720423889 | 501c3 | $21,530 | Medical Research |
| Univ of Minnesota Regents | |||||||
| 450 McNamara Alumni Center 200 Oak | Minneapolis | MN | 554552070 | 416007513 | Minnesota | $88,640 | Medical Research |
| Univ of Texas SW Med Ctr | |||||||
| Grants Management PO Box 841753 | Dallas | TX | 752841753 | 756002868 | Texas | $100,668 | Medical Research |
| University of Alabama at Birmingham | |||||||
| 1720 2nd Ave South AB 990 | Birmingham | AL | 35294 | 636005396 | Alabama | $27,190 | Medical Research |
| University of California Los Angeles | |||||||
| 11000 Kinross Ave Ste 211 | Los Angeles | CA | 90095 | 956006143 | 501c3 | $98,386 | Medical Research |
| University of California San Francisco | |||||||
| Controllers Office Contract Grants | San Francisco | CA | 941430897 | 946036493 | 501c3 | $7,804,108 | Medical Research |
| University of Chicago | |||||||
| 5841 S Maryland AveMC 5030 Room O-2 | Chicago | IL | 60637 | 362177139 | 501c3 | $156,821 | Medical Research |
| University of Colorado-Denver | |||||||
| PO Box 910238 | Denver | CO | 802910238 | 846000555 | 501c3 | $824,353 | Medical Research |
| University of Florida Board of Trustees | |||||||
| PO Box 113001 | Gainesville | FL | 32611 | 596002052 | 501c3 | $32,127 | Medical Research |
| University of Maryland Baltimore | |||||||
| Sponsored Projects Acctng 220 Arch | Baltimore | MD | 212011508 | 526002033 | Maryland | $14,555 | Medical Research |
| University of Miami | |||||||
| 1320 S Dixie Highway Gable One Towe | Coral Gables | FL | 331462926 | 590624458 | 501c3 | $24,027 | Medical Research |
| University of Michigan | |||||||
| Box 223131 | Pittsburgh | PA | 152512131 | 386006309 | 501c3 | $49,643 | Medical Research |
| University of Nebraska Medical Center | |||||||
| 985045 Nebraska Medical Center | Omaha | NE | 681985045 | 470049123 | 501c3 | $160,108 | Medical Research |
| University of North Carolina at Chapel Hill | |||||||
| PO Box 402420 Bank of America Lockb | Atlanta | GA | 303842420 | 566001393 | 501c3 | $395,036 | Medical Research |
| University of Oklahoma Health Sciences | |||||||
| 865 Research Parkway URP865-450 | Oklahoma City | OK | 731043609 | 731563627 | Oklahoma | $91,505 | Medical Research |
| University of Pennsylvania | |||||||
| PO Box 785541 | Philadelphia | PA | 171785541 | 231352685 | 501c3 | $227,089 | Medical Research |
| University of Pittsburgh | |||||||
| Research/Cost Accounting PO Box 371 | Pittsburgh | PA | 152517220 | 250965591 | 501c3 | $377,797 | Medical Research |
| University of Texas Southwestern Medical Center | |||||||
| Lock Box 845477 | Dallas | TX | 752845477 | 756002868 | Texas | $34,372 | Medical Research |
| University of Utah | |||||||
| Grants and Contract Accounting 201 | Salt Lake City | UT | 84132 | 876000525 | 501c3 | $18,175 | Medical Research |
| University of WA Grants | |||||||
| 12455 Collections Drive | Chicago | IL | 606930001 | 916001537 | Washington | $583,438 | Medical Research |
| University of Wisconsin Madison Board of Regents | |||||||
| 600 Highland AveF8/138 CSC | Madison | WI | 53792 | 396006492 | 501c3 | $249,654 | Medical Research |
| Vanderbilt University | |||||||
| Department of Finance Dept 1236 PO | Dallas | TX | 753121236 | 620476822 | 501c3 | $38,632 | Medical Research |
| Vital Prospects Clinical Research Institute PC | |||||||
| 7307 S Yale Ave Suite 200 | Tulsa | OK | 74136 | 261814411 | $110,900 | Medical Research | |
| Yale University | |||||||
| Grant and Contract Financial Admini | New Haven | CT | 065081873 | 080648973 | 501c3 | $362,716 | Medical Research |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 59 | Total501c3OrgCnt |
| Total Other Org | 5 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Part I Line 2 | FormAndLineReferenceDesc |
| Explanation | Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| First Class Or Charter Travel | Yes (X) | FirstClassOrCharterTravelInd |
| Written Policy Ref T And E Expnss | Yes (true) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (true) | SubstantiationRequiredInd |
| Severance Payment | false | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | false | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | false | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jane Buckner MD | |||||||||||
| Ex Officio, President | $314,832 | $24,000 | $936 | $339,768 | |||||||
| Carla Greenbaum MD | |||||||||||
| Director | $224,224 | $24,000 | $6,384 | $254,608 | |||||||
| Joyce Lammert MD PhD | |||||||||||
| Director | $467,090 | $25 | $19,220 | $14,846 | $11,630 | $512,811 | |||||
| John Corman MD | |||||||||||
| Director | $578,860 | $8 | $18,415 | $51,365 | $21,617 | $670,265 | |||||
| Gary Kaplan MD | |||||||||||
| Director | $1,103,978 | $285 | $23,334 | $27,255 | $41,740 | $1,196,592 | |||||
| Homer Lane Jr | |||||||||||
| Executive Director, CFO | $262,308 | $24,000 | $9,306 | $295,614 | |||||||
| Gerald Nepom MD PhD | |||||||||||
| Program Director, ITN | $149,222 | $24,000 | $3,192 | $176,414 | |||||||
| Willliam Kwok PhD | |||||||||||
| Research Member | $228,915 | $24,000 | $3,336 | $256,751 | $500 | ||||||
| Steven Ziegler PhD | |||||||||||
| Director of Academic Affairs | $220,724 | $16,824 | $4,788 | $242,336 | |||||||
| James Lord MD | |||||||||||
| Research Member | $199,380 | $17,634 | $4,476 | $221,490 | |||||||
| Lynn Rose PhD | |||||||||||
| Director Scientific Administration | $184,196 | $18,901 | $6,029 | $211,126 | $2,000 | ||||||
| Philip Bernstein | |||||||||||
| Research Member | $176,076 | $24,000 | $744 | $200,820 | |||||||
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Part I Line 3 | Benaroya Research Institute at Virginia Mason BRI delegates to Virginia Mason Health Systems its parent and sole member Board Compensation and Benefits Committee, a committee composed of independent Health System Board members to whom the BRI Board has delegated the authority to approve all compensation and benefits for the executive leaders of BRI. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. |
| Part I Line 4b | The Virginia Mason Medical Center has a Supplemental Executive Retirement Plan SERP in which certain BRI Executives participate. The SERP is a 457 f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into in connection with certain senior executives joining the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the Board delegates the authority to approve compensation and benefits to the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. Supplemental Executive Retirement Plans such as this are customary for senior executives in the health care industry. |
Schedule K IRS990ScheduleK
Tax Exempt Bonds Issues TaxExemptBondsIssuesGrp (2 entries)
| Bond ReferenceBondReferenceCd | Bond Issuer EINBondIssuerEIN | Bond IssuedBondIssuedDt | Issue PriceIssuePriceAmt | PurposePurposeDesc | DefeasedDefeasedInd | On Behalf Of IssuerOnBehalfOfIssuerInd | Pool FinancingPoolFinancingInd |
|---|---|---|---|---|---|---|---|
| WA Econ Devel Fin Auth-2012 Series B | |||||||
| A | 911493002 | 2012-06-01 | $10,390,000 | See Part VI | false | Yes (true) | false |
| WA Econ Devel Fin Auth-Series 2016 | |||||||
| B | 911493002 | 2016-06-01 | $18,631,490 | See Part VI | false | Yes (true) | false |
Tax Exempt Bonds Proceeds TaxExemptBondsProceedsGrp (2 entries)
| Bond ReferenceBondReferenceCd | RetiredRetiredAmt | Total ProceedsTotalProceedsAmt | Capital ExpendituresCapitalExpendituresAmt | Other Spent ProceedsOtherSpentProceedsAmt | Substantial CompletionSubstantialCompletionYr | Current RefundingCurrentRefundingInd | Advance RefundingAdvanceRefundingInd | Final Allocation MadeFinalAllocationMadeInd | Adequate Books And Rec MaintAdequateBooksAndRecMaintInd |
|---|---|---|---|---|---|---|---|---|---|
| A | $1,645,000 | $10,390,348 | $2,550,348 | $7,840,000 | 2013 | Yes (true) | false | Yes (true) | Yes (true) |
| B | $645,000 | $18,631,490 | $18,631,490 | Yes (true) | false | Yes (true) | Yes (true) |
Tax Exempt Bonds Private Bus Use TaxExemptBondsPrivateBusUseGrp (2 entries)
| Bond ReferenceBondReferenceCd | Owning Bond Financed PropertyOwningBondFinancedPropertyInd | Any Lease ArrangementsAnyLeaseArrangementsInd | Mgmt Contract Bond Fincd PropMgmtContractBondFincdPropInd | Any Research AgreementsAnyResearchAgreementsInd | Engage Bond Counsel ResearchEngageBondCounselResearchInd | Private Bus Use By OthersPrivateBusUseByOthersPct | Total Private Business UseTotalPrivateBusinessUsePct | Bond Iss Meet Prvt Sec Pymt TestBondIssMeetPrvtSecPymtTestInd | Change In Use Bond Financed PropChangeInUseBondFinancedPropInd | Procs Nonqualified Bond RemdtdProcsNonqualifiedBondRemdtdInd |
|---|---|---|---|---|---|---|---|---|---|---|
| A | false | Yes (true) | false | Yes (true) | Yes (true) | 0.01630 | 0.01630 | false | false | Yes (true) |
| B | false | Yes (true) | false | Yes (true) | Yes (true) | 0.01630 | 0.01630 | false | false | Yes (true) |
Tax Exempt Bonds Arbitrage TaxExemptBondsArbitrageGrp (2 entries)
| Bond ReferenceBondReferenceCd | Form8038 T FiledForm8038TFiledInd | Rebate Not Due YetRebateNotDueYetInd | Variable Rate IssueVariableRateIssueInd | Hedge Identified In Bks And RecHedgeIdentifiedInBksAndRecInd | Gross Proceeds Invested In GICGrossProceedsInvestedInGICInd | Gross Proceeds InvestedGrossProceedsInvestedInd | Written Proc To Monitor ReqsWrittenProcToMonitorReqsInd |
|---|---|---|---|---|---|---|---|
| A | false | Yes (true) | false | false | false | false | Yes (true) |
| B | false | Yes (true) | false | false | false | false | Yes (true) |
Procedures Corrective Action ProceduresCorrectiveActionGrp (2 entries)
| Bond ReferenceBondReferenceCd | Procedures Corrective ActionProceduresCorrectiveActionInd |
|---|---|
| A | Yes (true) |
| B | Yes (true) |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Part I Line A Column F | Purposes to currently refund WEDFA Series 2006C bonds issued 11/15/2006, and to fund research facility improvements. |
| Part I Line B Column F | Purposes to currently refund WEDFA Series 2012A taxable bonds issued 06/01/2012. No tax-exempt private activity bonds are being refunded. |
| Part III Line 3 | Difference between Part I, column e and Part II, line 3 is investment earnings. |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (12 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Form 990, Part III, Line 1 | Benaroya Research Institute at Virginia Mason BRI is a world-renowned medical research institute whose work has resulted in major advances in our understanding of autoimmune and immune-mediated diseases. BRI is affiliated with the Virginia Mason Health System, which provides governance oversight and development support through the Virginia Mason Foundation. In 2017, BRI scientists led four international centers for autoimmune disease research and collaborated with colleagues all over the world. These researchers generated 76 scientific publications that were published in prestigious research journals, delivered 133 presentations at domestic and international research conferences and received many major grants. Nearly half of BRIs research faculty also serve as affiliate professors at the University of Washington and mentor postdoctoral fellows, graduate students and summer interns. Their leadership, expertise, collaboration, dedication and curiosity drive our pioneering discoveries. Information about the diseases that BRI studies One in 15 Americans suffers from one of the more than 80 known autoimmune diseases, and 25 of these people suffer from more than one of these interrelated diseases. Autoimmune diseases include type 1 diabetes, multiple sclerosis, Crohns disease and rheumatoid arthritis to name a few. Even more Americans, one out of every four, suffer from other immune-mediated diseases, allergy and asthma. These are all lifelong conditions, currently without a cure. Because these diseases are connected by common destructive pathways, research on one or two immune system diseases has far reaching implications for the whole spectrum of immune-mediated disease. As a world leader in scientific innovation, BRIs discoveries are having significant impact on people living with these diseases today - by improving the ability to predict disease risk, prevent onset of disease, decrease disease progression, make treatments safer and better - while striving to ultimately cure these diseases. |
| Form 990, Part III, Line 4 | One of the unique qualities of BRI is the close integration of three types of medical research - laboratory research, translational research and clinical research - to improve peoples lives. Our scientists can address both the basic science issues and clinical applications, which is the best way to design studies with the highest potential for success. For BRI, discovery starts in the laboratory but is driven by patient issues addressed in the clinic. 2017 advancements in immunology, translational research, clinical research and other areas are highlighted below. |
| Form 990, Part III, Line 4a | Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually supports the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in three clinical areas asthma and allergic diseases autoimmune diseases and immune-mediated rejection of transplanted solid organs, tissues and cells. As the Prime recipient of this grant, BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2017 were diverse, but continued to center on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2017 include the following 1 Cross Network Integration A top priority in this reporting period was to continue the successful ITN infrastructure which is spread across three main operational sites. This required careful planning and collaboration as the ITNs major centers of operations are geographically diverse, located in Seattle, San Francisco and Bethesda. Few changes were made to the existing network integration as the current model continues to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. 2 Operations and Clinical Trial Support The ITN program team at BRI issued 154 subawards in 2017 in support of 20 active ITN clinical trials and numerous supporting ITN mechanistic trials. 3 Supplemental Funding / Partnerships ITN central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. a Supplemental Funding Opportunities The ITN Program Team at BRI submitted one supplemental funding request in 2017. This request was awarded, bringing in an additional 2.9M in funding to the ITN BRI. b Partnerships The ITN added one pharmaceutical partner providing partial support for a new clinical trial and continued its relationship with two other pharmaceutical partners for partial funding on two ongoing ITN studies. NIAID is the clinical sponsor on all three of these trials. 4 Publication Activity In 2017, 29 ITN publications were published in prestigious research journals and were presented at domestic and international research conferences. These publications represented ITN research in all therapeutic focus areas of the ITN Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. |
| Form 990, Part III, Line 4b | Translational research is a scientific approach that allows reserch observations made in the basic research lab to be quickly tested in the clinic with patients, and results brought back to the lab again in an expedient and systematic way. This research is translating new methods that improve our ability to predict disease risk, prevent onset of disease, decrease disease progression and make treatments safer and better. The research emphasis of the BRI Translational Research Program is in the areas of autoimmune and immune-mediated diseases. BRI scientists and physician collaborators work together to study blood and serum samples along with medial and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy and asthma. BRI maintains an extensive biorepository with samples dating back to 2000, including eight disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2017 include the following 1 Gene Editing Work Continues - BRI and Seattle Childrens Research Institute SCRI are collaborating on a preclinical study pioneering the use of gene editing techniques in efforts to control type 1 diabetes. By isolating the cells that attack the pancreas in type 1 diabetes and reprograming them by editing their genes, there is the hope that this could provide an important step forward in efforts to cure type 1 diabetes and possibly other diseases. To attack this complex problem, BRI is combing its regulatory T cell expertise with SCRIs gene editing expertise. 2 Study Launched to Understand Immune Cell Malfunction - BRI received a grant to help explain why immune cells cause type 1 diabetes, multiple sclerosis, rheumatoid arthritis and many other autoimmune diseases. This will enable BRI researchers to investigate a key mystery Do excess amounts of a chemical called interleukin-6 IL-6 - or an exaggerated response to it - cause T cells to mistake the bodys cells as enemies and attack them Using T cells in blood samples donated to BRIs biorepositories, scientists will try to pinpoint why some T-cells have more IL-6 receptors than others. The researchers will also examine how excess IL-6 changes how T cells function in healthy people and in people with type 1 diabetes, multiple sclerosis and rheumatoid arthritis. 3 Discovery of How Gene Variation Drives Autoimmune Disease - BRI researchers, in collaboration with three other institutions, helped discover that a variation in the gene IFIH1 simultaneously increases the risk of autoimmune disease and helps protect against viruses. The team used model systems and blood cells donated by healthy people to study the IFIH1 variation linked with autoimmunity. The researchers found that the IFIH1 variation enhances how the immune system responds to certain viruses, making it more likely the body will defeat them. But this protection comes with a price the immune system is more likely to mistake the bodys own cells as foreign invaders. This kicks off autoimmune attacks that are the hallmarks of type 1 diabetes, lupus and other autoimmune diseases. 4 Preventing Rheumatoid Arthritis - In the study called TIP-RA Targeting Immune Responses for the Prevention of Rheumatoid Arthritis BRI scientists, in collaboration with three other academic institutions, are looking for ways to prevent rheumatoid arthritis RA from occurring in people with a high risk of the disease. By using single cell analysis, researchers now have the capacity to take a small amount of human blood and look in-depth at specific T cells targeting the joints in RA, to understand what makes them become harmful and attack the body. Once scientists understand what starts RA, then approaches can be developed to stop the disease before it takes hold. |
| Form 990, Part III, Line 4c | BRI is dedicated to seeking ways to eliminate type 1 diabetes, while at the same time looking for therapies to prevent, reverse and intervene in the disease at all stages. BRI is an international leader in type 1 diabetes research and has investigated it for more than 30 years, starting with identification of a genetic marker for the disease. BRI continues to lead the Type 1 Diabetes TrialNet, a National Institutes of Health-funded clinical trial network for type 1 diabetes prevention and early treatment. BRI also serves as the TrialNet Hub that includes 23 clinical centers working in cooperation with more than 200 screening and clinical research sites throughout the U.S. and six other countries. Progress in 2017 includes 1 Insulin Pill Study Results TrialNet led the largest study using oral insulin, testing the effect of insulin pills on 560 children and adults whose relatives had type 1 diabetes. For most, the drug had no effect on whether or not they developed type 1 diabetes or how quickly they developed it. But for those at the highest risk of developing the disease, sooner rather than later, insulin pill therapy delayed the time it took to develop the full-blown disease by about two-and-a-half years. 2 Discovery of Unique T cells - BRI researchers recently discovered that patients with type 1 diabetes have a unique set of T cells that have grown and multiplied, increasing the number of bad cells that can attack the pancreas. These unique T cells are rare in healthy individuals, but they exist in significantly higher numbers in patients with type 1 diabetes. Thanks to past technology breakthroughs made at BRI, scientists can find and capture the rare destructive T cells from the thousands of other cells in a drop of blood. Combining this method for capturing the T cells with new technology called single cell RNA sequencing, these cells can now be studied - one cell at a time - in extraordinary detail. This information is then used to decode the bad cells and find out what makes them tick. |
| Form 990, Part III, Line 4d | 1 Clinical Research Program Benaroya Research Institute oversees all clinical research at Virginia Mason Medical Center which uniquely combines the expertise of a world-renowned medical reserach institute with the remarkable care of a healthcare quality leader. The BRI Clinical Research Program supports Virginia Mason clinical investigators in studies across a wide variety of autoimmune and immune-mediated diseases and conditions, as well as a broad range of other diseases such as cancer and cardiac disease. Each year the Clinical Research Program staff annually enrolls approximately 1500 study participants into Virginia Mason trials. This program involves approximately 150 research investigators, oversees 460 active studies and has 110 studies currently open to enrollment. 2 Immunology Research Program Groundbreaking allergy finding - In collaboration with Virginia Mason physicians and their patients blood samples donated to the biorepository combined with tools and techniques of single cell analysis, a groundbreaking allergy discovery was made, altering the course of allergy research. The cell that appears to drive all allergies was identified and named TH2A, providing a promising target for improving diagnosis, monitoring and treatment of all allergies. These cells could be used as biomarkers, or indicators, that show whether a person has an allergy or is responding to allergy therapy. The hope is to at some point be able to identify a signature from a drop of blood that will predict the presence of an allergy long before the first symptoms are experienced. New Clues to Autoimmune Skin Diseases - A team of scientists recently identified a new population of immune cells in the blood that closely resembles immune cells in the skin. They accomplished this by using BRIs combination of expertise, cutting-edge techniques and the latest equipment. While researchers currently know how to isolate immune cells from the blood, immune cells in tissue are difficult to isolate and study, therefore their functions are still poorly understood. Identification of cells in the blood that are related to these immune cells would help scientists better define their functions in health and in disease. This discovery led to a surprising finding these cells may play a vital role not only in protecting us from infection, but also in helping repair damaged tissue. This raises the possibility, and hope, that science can harness these cells for treatment of chronic wounds and autoimmune skin diseases such as scleroderma, psoriasis and atopic dermatitis. New System Model of Multiple Sclerosis Developed - Developed by a BRI researcher, this new system model of multiple sclerosis MS articulates more fully the many complexities of this disease. Scientists can see how the disease progresses and look for better therapies and ways to prevent onset. The model includes several groundbreaking features and studies a factor, the STAT1 gene, shown to have an important role in MS. The new system model is unique because it allows researchers to see what is happening in the central nervous system - the brain and the spinal cord - as well as the immune system, in real time. What is done with system models can potentially lead to new translational and clinical studies that impact disease diagnosis and therapies. Lupus Research Moves Forward - BRI researchers are making important progress in their understanding of what causes lupus through discovery of a novel protein that controls the production of type 1 interferon that could be a target for therapies. Additionally, discovery of a new molecular pathway in lupus that doesnt function properly when people develop lupus is being studied using blood samples of people with and without lupus from the biorepository. Using tetramers, a lab is further investigating the role of T cells in development of lupus. 3 Systems Immunology Division The Systems Immunology Division expanded its scope and resources so as to make single cell analysis available to all areas of the institute. Systems Immunology staff includes PhD computational biologists and biostatisticians with access to a high-performance computing infrastructure and specialized software. By profiling cells at the single cell level, researchers can determine how they are related to each other and how they are related to disease processes. By using sophisticated technologies and data analytics, its possible to read and interpret the molecular blueprints driving cell function, showing the immune system differences that occur during health, disease or during therapy. And with each discovery of important pathways or cells, scientists can then build model systems to confirm whether or not the discovery plays a critical role in immunity. These pathways or cells can then be targets for therapies to eliminate diseases and bring the immune system into balance again. |
| Form 990, Part VI, Section A, Line 1a | The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The President and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all of the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. |
| Form 990, Part VI, Section A, Line 6,7 | Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. |
| Form 990, Part VI, Section B, Line 11b | The VMHS Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including a selection, engagement, and review of the performance of the independent tax preparer b review of the annual draft Form 990 tax return, and c recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provide the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final draft Form 990 is reviewed and approved by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. |
| Form 990, Part VI, Section B, Line 12c | The VMHS Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Management Plan be maintained. |
| Form 990, Part VI, Section B, Line 15 | The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee of BRI Executives consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2017 were the Board Director, Carla Greenbaum, the former BRI Director, Gerald Nepom the BRI President and the Executive Director and Chief Financial Officer. |
| Form 990, Part VI, Section C, Line 19 | The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (4 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd |
|---|---|---|---|---|---|---|---|---|---|---|
| Virginia Mason Health System (VMHS) | ||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 911351110 | Fundraising | WA | Sec 501c3 | 7 | NA | Yes (true) |
| Virginia Mason Medical Center | ||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 910565539 | Health Care | WA | Sec 501c3 | 3 | VMHS | false |
| Virginia Mason Institute | ||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 263763656 | Education/Research | WA | Sec 501c3 | 9 | VMMC | false |
| Yakima Valley Memorial Hospital Association | ||||||||||
| 2811 Tieton Drive | Yakima | WA | 98902 | 910567263 | Health Care | WA | Sec 501c3 | 3 | VMHS | false |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (true) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | false | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | Yes (true) | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | Yes (true) | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (true) | SharingOfFacilitiesInd |
| Paid Employees Sharing | false | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | Yes (true) | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | Yes (true) | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | false | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Affiliated Group Schedule AffiliatedGroupSchedule
Affiliated Schedule AffiliatedScheduleGrp (5 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Total Grassroots LobbyTotalGrassrootsLobbyAmt | Total Direct LobbyTotalDirectLobbyAmt | Total Lobby ExpenditureTotalLobbyExpenditureAmt | Other Exempt Purpose ExpendOtherExemptPurposeExpendAmt | Total Exempt Purpose ExpendTotalExemptPurposeExpendAmt | Lobby NontxLobbyNontxAmt | Grassroots NontxGrassrootsNontxAmt | Total Lobby Grssroot Mns NontxTotalLobbyGrssrootMnsNontxAmt | Tot Lbby Expend Mns Lobby NontxTotLbbyExpendMnsLobbyNontxAmt | Share Excess Lobby ExpendShareExcessLobbyExpendAmt | Electing OrganizationElectingOrganizationInd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benaroya Research Institute at Virginia Mason | |||||||||||||||
| 1201 Ninth Avenue | Seattle | WA | 98101 | 910653422 | $0 | $0 | $0 | $71,612,353 | $71,612,353 | $45,128 | $11,282 | $0 | $0 | $0 | |
| Virginia Mason Health System | |||||||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 911351110 | $0 | $0 | $0 | $12,576,341 | $12,576,341 | $7,925 | $1,981 | $0 | $0 | $0 | |
| Virginia Mason Medical Center | |||||||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 910565539 | $133,386 | $48,767 | $182,153 | $1,029,259,580 | $1,029,441,733 | $648,719 | $162,180 | $0 | $0 | $0 | Yes (X) |
| Virginia Mason Institute | |||||||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 263763856 | $0 | $0 | $0 | $7,028,082 | $7,028,082 | $4,429 | $1,107 | $0 | $0 | $0 | |
| Yakima Valley Memorial Hospital Association | |||||||||||||||
| 2811 Tieton Drive | Seattle | WA | 98902 | 910567263 | $42,094 | $60,000 | $102,094 | $466,123,588 | $466,225,682 | $293,799 | $73,450 | $0 | $0 | $0 | |